451 related articles for article (PubMed ID: 24473991)
1. New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations.
Bleau AM; Freire J; Pajares MJ; Zudaire I; Anton I; Nistal-Villán E; Redrado M; Zandueta CN; Garmendia I; Ajona D; Blanco D; Pio R; Lecanda F; Calvo A; Montuenga LM
Int J Cancer; 2014 Dec; 135(11):2516-27. PubMed ID: 24473991
[TBL] [Abstract][Full Text] [Related]
2. miR-134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene.
Liu CJ; Shen WG; Peng SY; Cheng HW; Kao SY; Lin SC; Chang KW
Int J Cancer; 2014 Feb; 134(4):811-21. PubMed ID: 23824713
[TBL] [Abstract][Full Text] [Related]
3. Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer.
Belmont L; Rabbe N; Antoine M; Cathelin D; Guignabert C; Kurie J; Cadranel J; Wislez M
Int J Cancer; 2014 Feb; 134(4):765-77. PubMed ID: 23913633
[TBL] [Abstract][Full Text] [Related]
4. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
5. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.
Guin S; Ru Y; Wynes MW; Mishra R; Lu X; Owens C; Barn AE; Vasu VT; Hirsch FR; Kern JA; Theodorescu D
J Thorac Oncol; 2013 Dec; 8(12):1492-501. PubMed ID: 24389431
[TBL] [Abstract][Full Text] [Related]
6. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-708-5p acts as a therapeutic agent against metastatic lung cancer.
Wu X; Liu T; Fang O; Dong W; Zhang F; Leach L; Hu X; Luo Z
Oncotarget; 2016 Jan; 7(3):2417-32. PubMed ID: 26678031
[TBL] [Abstract][Full Text] [Related]
8. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
9. MiR-503 targets PI3K p85 and IKK-β and suppresses progression of non-small cell lung cancer.
Yang Y; Liu L; Zhang Y; Guan H; Wu J; Zhu X; Yuan J; Li M
Int J Cancer; 2014 Oct; 135(7):1531-42. PubMed ID: 24550137
[TBL] [Abstract][Full Text] [Related]
10. IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.
Caetano MS; Zhang H; Cumpian AM; Gong L; Unver N; Ostrin EJ; Daliri S; Chang SH; Ochoa CE; Hanash S; Behrens C; Wistuba II; Sternberg C; Kadara H; Ferreira CG; Watowich SS; Moghaddam SJ
Cancer Res; 2016 Jun; 76(11):3189-99. PubMed ID: 27197187
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of the TGFβ Pseudoreceptor BAMBI in Non-Small Cell Lung Cancer Enhances TGFβ Signaling and Invasion.
Marwitz S; Depner S; Dvornikov D; Merkle R; Szczygieł M; Müller-Decker K; Lucarelli P; Wäsch M; Mairbäurl H; Rabe KF; Kugler C; Vollmer E; Reck M; Scheufele S; Kröger M; Ammerpohl O; Siebert R; Goldmann T; Klingmüller U
Cancer Res; 2016 Jul; 76(13):3785-801. PubMed ID: 27197161
[TBL] [Abstract][Full Text] [Related]
12. Cytoplasmic Ape1 expression elevated by p53 aberration may predict survival and relapse in resected non-small cell lung cancer.
Wu HH; Chu YC; Wang L; Tsai LH; Lee MC; Chen CY; Shieh SH; Cheng YW; Lee H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S336-47. PubMed ID: 22688662
[TBL] [Abstract][Full Text] [Related]
13. Activation of RAS family members confers resistance to ROS1 targeting drugs.
Cargnelutti M; Corso S; Pergolizzi M; Mévellec L; Aisner DL; Dziadziuszko R; Varella-Garcia M; Comoglio PM; Doebele RC; Vialard J; Giordano S
Oncotarget; 2015 Mar; 6(7):5182-94. PubMed ID: 25691052
[TBL] [Abstract][Full Text] [Related]
14. Bmi1 regulates cell fate via tumor suppressor WWOX repression in small-cell lung cancer cells.
Kimura M; Takenobu H; Akita N; Nakazawa A; Ochiai H; Shimozato O; Fujimura Y; Koseki H; Yoshino I; Kimura H; Nakagawara A; Kamijo T
Cancer Sci; 2011 May; 102(5):983-90. PubMed ID: 21276135
[TBL] [Abstract][Full Text] [Related]
15. ING5 inhibits cancer aggressiveness via preventing EMT and is a potential prognostic biomarker for lung cancer.
Zhang F; Zhang X; Meng J; Zhao Y; Liu X; Liu Y; Wang Y; Li Y; Sun Y; Wang Z; Mei Q; Zhang T
Oncotarget; 2015 Jun; 6(18):16239-52. PubMed ID: 25938545
[TBL] [Abstract][Full Text] [Related]
16. Reversing effect of exogenous WWOX gene expression on malignant phenotype of primary cultured lung carcinoma cells.
Zhou YL; Li YC; Shou F; Liu CQ; Pu Y; Tang H
Chin Med J (Engl); 2010 Mar; 123(5):615-20. PubMed ID: 20367991
[TBL] [Abstract][Full Text] [Related]
17. Aldehyde dehydrogenase 1A1 possesses stem-like properties and predicts lung cancer patient outcome.
Li X; Wan L; Geng J; Wu CL; Bai X
J Thorac Oncol; 2012 Aug; 7(8):1235-45. PubMed ID: 22617249
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of the putative oncogene COTE1 contributes to human hepatocarcinogenesis through modulation of WWOX signaling.
Zhang H; Tian Y; Shen J; Wang Y; Xu Y; Wang Y; Han Z; Li X
Int J Oncol; 2014 Aug; 45(2):719-31. PubMed ID: 24899407
[TBL] [Abstract][Full Text] [Related]
19. Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway.
Sun Y; Chen C; Zhang P; Xie H; Hou L; Hui Z; Xu Y; Du Q; Zhou X; Su B; Gao W
Sci Rep; 2014 Oct; 4():6527. PubMed ID: 25284075
[TBL] [Abstract][Full Text] [Related]
20. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
